

Interim report 1 January – 30 June 2022

A quarter in change


1 APRIL – 30 JUNE 2022 (3 MONTHS)

- Net sales decreased by 9 percent to SEK 2,079m (2,276), of which acquired growth amounted to 13 percent. The COVID-19 related net sales decreased by 88 percent. The organic growth, excluding net sales related to COVID-19, was 4 percent.
- EBITA decreased by 28 percent to SEK 240m (332), corresponding to an EBITA-margin of 11.6 percent (14.6).
- Profit after tax decreased by 57 percent to SEK 76m (178).
- Earnings per share amounted to SEK 0.63 (1.47).
- Cash flow from operating activities amounted to SEK 206m (200).
- During the quarter, two acquisitions, BioCat GmbH and O'Flynn Medical Ltd, were completed and after the end of the quarter, one more acquisition, JK Lab Nordic AB, were completed. In total, these acquisitions are estimated to contribute with annual net sales of approximately SEK 180m and approximately 60 employees.


1 JANUARY – 30 JUNE 2022 (6 MONTHS)

- Net sales increased by 16 percent to SEK 4,658m (4,012), of which acquired growth amounted to 30 percent. The COVID-19 related net sales decreased by 59 percent. The organic growth, excluding net sales related to COVID-19, was 3 percent.
- EBITA increased by 3 percent to SEK 675m (658), corresponding to an EBITA-margin of 14.5 percent (16.4).
- Profit after tax decreased by 26 percent to SEK 301m (404).
- Earnings per share amounted to SEK 2.47 (3.46). Earnings per share for the last 12 months amounted to SEK 5.07 (6.03).
- Cash flow from operating activities amounted to SEK 538m (384).
- The equity ratio was 36 percent (40).
- Return on working capital (P/WC) amounted to 74 percent (95).
- During the interim period, four acquisitions were made and another after the end of the interim period. The acquisitions are expected to contribute with annual net sales of approximately SEK 855m.
- AddLife's new President and CEO Fredrik Dalborg will start on September 1st.

SEKm	3 months ending			6 months ending			12 months ending	
	30 Jun 22	30 Jun 21	change	30 Jun 22	30 Jun 21	change	30 Jun 22	31 Dec 21
Net sales	2,079	2,276	-9%	4,658	4,012	16%	8,639	7,993
EBITA	240	332	-28%	675	658	3%	1,290	1,273
EBITA-margin, %	11.6%	14.6%		14.5%	16.4%		14.9%	15.9%
Profit before tax	94	237	-60%	383	524	-27%	786	927
Profit for the period	76	178	-57%	301	404	-26%	618	721
Earnings per share before dilution, SEK	0.63	1.47	-57%	2.47	3.46	-29%	5.07	6.03
Earnings per share after dilution, SEK	0.62	1.46	-58%	2.46	3.44	-28%	5.04	6.01



■ Quarter
— Rolling 12 months



■ Quarter
— Rolling 12 months

ADDLIFE IN BRIEF

AddLife is an independent provider in Life Science that offers high-quality products, services and advice to both the private and public sector in Europe. The Group is divided into two business areas: Labtech and Medtech. The Group comprises some 85 operating subsidiaries that provide equipment, instruments, medical devices and reagents, as well as advice and technical support to customers primarily in healthcare, research and academia, along with the food and pharmaceutical industries.

CONFERENCE CALL

Investors, analysts and the media are invited to a conference call where CEO Kristina Willgård and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10:00 a.m. on July 15th, 2022

If you wish to participate via teleconference, [please follow this link](#)>>

Or call in (only sound) +46 8 505 376 58 Conferens-ID: 915 124 356#

The presentation is also available on [AddLife YouTube](#) >>